The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Intratumoral immunotherapy with TLR7/8 agonist MEDI9197 modulates the tumor microenvironment leading to enhanced activity when combined with other immunotherapies
Open accessAbstract
Background Immune checkpoint blockade (ICB) promotes adaptive immunity and tumor regression in some cancer patients. However, in patients with immunologically “cold” tumors, tumor-resident innate immune cell activation may be required to prime an adaptive immune response and so exploit the full potential of ICB. Whilst Toll-like receptor (TLR) agonists have been used topically to successfully treat some superficial skin tumors, systemic TLR agonists have not been well-tolerated. Methods The response of human immune cells to TLR7 and 8 agonism was measured in primary human immune cell assays. MEDI9197 (3M-052) was designed as a novel lipophilic TLR7/8 agonist that is retained at the injection site, limiting systemic exposure. Retention of the TLR7/8 agonist at the site of injection was demonstrated using quantitative whole-body autoradiography, HPLC-UV, and MALDI mass spectrometry imaging. Pharmacodynamic changes on T cells from TLR7/8 agonist treated B16-OVA tumors was assessed by histology, quantitative real time PCR, and flow cytometry. Combination activity of TLR7/8 agonism with immunotherapies was assessed in vitro by human DC-T cell MLR assay, and in vivo using multiple syngeneic mouse tumor models. Results Targeting both TLR7 and 8 triggers an innate and adaptive immune response in primary human immune cells, exemplified by secretion of IFNα, IL-12 and IFNγ. In contrast, a STING or a TLR9 agonist primarily induces release of IFNα. We demonstrate that the TLR7/8 agonist, MEDI9197, is retained at the sight of injection with limited systemic exposure. This localized TLR7/8 agonism leads to Th1 polarization, enrichment and activation of natural killer (NK) and CD8+ T cells, and inhibition of tumor growth in multiple syngeneic models. The anti-tumor activity of this TLR7/8 agonist is enhanced when combined with T cell-targeted immunotherapies in pre-clinical models. Conclusion Localized TLR7/8 agonism can enhance recruitment and activation of immune cells in tumors and polarize anti-tumor immunity towards a Th1 response. Moreover, we demonstrate that the anti-tumor effects of this TLR7/8 agonist can be enhanced through combination with checkpoint inhibitors and co-stimulatory agonists.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J. M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014) · Nature · doi:10.1038/nature13954 · Cited by 6,609
Kadowaki, N., Ho, S., Antonenko, S., de Waal Malefyt, R., Kastelein, R. A., Bazan, F., & Liu, Y.-J. (2001) · The Journal of Experimental Medicine · doi:10.1084/jem.194.6.863 · Cited by 1,964
Van Hoeven, N., Fox, C. B., Granger, B., Evers, T., Joshi, S. W., Nana, G. I., Evans, S. C., Lin, S., Liang, H., Liang, L., et al. (2017) · Scientific Reports · doi:10.1038/srep46426 · Cited by 87
Self-citation
Cited by
Toll-Like Receptor Signaling and Its Role in Cell-Mediated Immunity
Duan, T., Du, Y., Xing, C., Wang, H. Y., & Wang, R.-F. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.812774 · Cited by 972
Immune checkpoint therapy for solid tumours: clinical dilemmas and future trends
Sun, Q., Hong, Z., Zhang, C., Wang, L., Han, Z., & Ma, D. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01522-4 · Cited by 598
Current Strategies to Target Tumor-Associated-Macrophages to Improve Anti-Tumor Immune Responses
Anfray, C., Ummarino, A., Andón, F. T., & Allavena, P. (2019) · Cells · doi:10.3390/cells9010046 · Cited by 304
Bahmani, B., Gong, H., Luk, B. T., Haushalter, K. J., DeTeresa, E., Previti, M., Zhou, J., Gao, W., Bui, J. D., Zhang, L., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-22311-z · Cited by 299
Ni, H., Zhang, H., Li, L., Huang, H., Guo, H., Zhang, L., Li, C., Xu, J.-X., Nie, C.-P., Li, K., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-005151 · Cited by 85
Metadata
- Authors
- Mullins, S. R., Vasilakos, J. P., Deschler, K., Grigsby, I., Gillis, P., John, J., Elder, M. J., Swales, J., Timosenko, E., Cooper, Z., Dovedi, S. J., Leishman, A. J., Luheshi, N., Elvecrog, J., Tilahun, A., Goodwin, R., Herbst, R., Tomai, M. A., & Wilkinson, R. W.
- Venue
- Journal for ImmunoTherapy of Cancer
- Publisher
- BMJ
- Published
- 2019-09-11
- Volume
- 7
- Issue
- 1
- Pages
- 244-244
- ISSN
- 2051-1426 (ISSN-L)
- OpenAlex
- W2973192833
- Cited by
- 186
- References
- 3
- FWCI
- 8.49
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Intratumoral immunotherapy with TLR7/8 agonist MEDI9197 modulates the tumor microenvironment leading to enhanced activity when combined with other immunotherapies. https://app.cochat.ai/papers/10.1186/s40425-019-0724-8
- The paper
- Mullins, S. R., Vasilakos, J. P., Deschler, K., Grigsby, I., Gillis, P., John, J., Elder, M. J., Swales, J., Timosenko, E., Cooper, Z., Dovedi, S. J., Leishman, A. J., Luheshi, N., Elvecrog, J., Tilahun, A., Goodwin, R., Herbst, R., Tomai, M. A., & Wilkinson, R. W. (2019). Intratumoral immunotherapy with TLR7/8 agonist MEDI9197 modulates the tumor microenvironment leading to enhanced activity when combined with other immunotherapies. Journal for ImmunoTherapy of Cancer. https://doi.org/10.1186/s40425-019-0724-8
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.